Mohammad Vaziri Shares Breakthrough Insights on Factor XI Inhibitors for Thrombosis Prevention and Safer Anticoagulation
Mohammad Vaziri, Thoracic Surgery Professional at IRAN University of Medical Sciences (IUMS), posted on LinkedIn:
”Key points
Factor XI (FXI) inhibitors aim to uncouple hemostasis from thrombosis, presenting a novel approach to anticoagulation, with a reduced risk of bleeding compared with that associated with traditional anticoagulant agents.
Several phase II studies indicate that FXI inhibitors decrease thrombotic complications dose-dependently, without corresponding increases in bleeding, suggesting a favourable safety profile.
FXI inhibitors showed non-inferiority and potential superiority to low-molecular-weight heparin for the prevention of venous thromboembolism in patients undergoing orthopaedic surgery, with minimal bleeding risks observed at therapeutic doses.
Milvexian and abelacimab are theoretically promising for reducing the risk of bleeding associated with thromboprophylaxis in patients with atrial fibrillation; phase III clinical trials of safety and efficacy are ongoing.
In phase II trials involving patients with non-cardioembolic ischaemic stroke, no significant benefit of FXI inhibitors was found in terms of the primary ischaemic end points, but future phase III trials might find benefits in selected patients with large-vessel atherosclerosis.
The ongoing LIBREXIA-ACS trial will assess the use of milvexian in 16,000 patients with recent acute coronary syndrome.”
Reaf the full article here.
Title: Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism
Authors: Davide Capodanno, John H. Alexander, M. Cecilia Bahit, John W. Eikelboom, C. Michael Gibson, Shaun G. Goodman, Vijay Kunadian, Gregory Y. H. Lip, Renato D. Lopes, Roxana Mehran, Shamir R. Mehta, Manesh R. Patel, Jonathan P. Piccini, Sunil V. Rao, Christian T. Ruff, P. Gabriel Steg, Jeffrey I. Weitz, Dominick J. Angiolillo
Stay updated with Hemostasis Today.
-
Aug 12, 2026, 07:49Alan Dursun: Phnom Penh, Cambodia – Part 3 – Turning Partnership into Action
-
Aug 12, 2026, 06:55Alejandro González Veliz: A Good PCI is not Just about Opening the Artery
-
Aug 12, 2026, 06:39Abdulmalik Alnuqydan: Why Do We Transfuse RBCs Less Than 7 Days Old to Newborns?
-
Aug 12, 2026, 06:24Lucas Jae: How Mitochondria Sense Heme Scarcity to Regulate Heme and Globin Production
-
Aug 12, 2026, 06:09Luis Tam։ New CDC Global Health Security Funding Opportunities
-
Aug 12, 2026, 06:09Yan Leyfman: Curative Strategies and Precision Medicine in Sickle Cell Disease
-
Aug 12, 2026, 06:01Sophie He: Exploring Manufacturing Scalability and Cell Separation
-
Aug 12, 2026, 05:54Yuan Goessi: One Bleed Is One Too Many for a Lifetime of Haemophilia A
-
Aug 12, 2026, 05:47Shehab Mohamed: Philadelphia Negative MPNs in AYA vs Older Adults in Qatar